Targeting Hepatic Glucokinase in Type 2 Diabetes
Year: 2008
Type: article
Abstract: Glucokinase (hexokinase IV) has a major role inthe control of blood glucose homeostasis be-cause it is the predominant hexokinase ex-pressed in the liver, has a very high control strength on hepatic glucose disposal (1), and is the glucose sensor for insulin secretion in pancreatic -cells (2). Glucokinase is currently considered a strong candidate target for antihyperglycemic drugs for type 2 diabetes (2–4). This is supported by the impact of mutations in the glucokinase gene on blood glucose concentration in hu-mans. Inactivating mutations that lower the enzyme affin-ity for glucose or compromise glucokinase expression cause diabetes (maturity onset diabetes of the young type 2), whereas activating mutations lower blood glucose (2). Pharmacological activators of glucokinase (GKAs) that mimic the effect of activating mutations represent a poten-tial novel strategy for antihyperglycemic therapy (2–4). Type 2 diabetes is associated with defective regulation
Source: Diabetes
DOI: 10.2337/db08-1470
Author: Loranne Agius
Institution: Newcastle University
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W2471356895